Can fake ayurveda medicines cure sexual disorders, impotency? Seizures by Drug Control Admn

HYDERABAD: The Telangana Drugs Control Administration (DCA) has seized eight varieties of ayurvedic medicines from Nalgonda for making misleading claims on their labels and violating the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

The medicines, manufactured by Lifecare Ayurvedic from Rajasthan, made claims to treat diabetes, kidney stones, sexual impotence, obesity, asthma, menstrual disorders, and vision problems, which are prohibited under the Act.

The seized products are

  • Diab Amrit Capsules (claimed to treat diabetes)
  • Stone Crush Capsules and Syrup (claimed to treat kidney stones)
  • Sleemocare Kit Powder and Capsule (claimed to treat obesity)
  • Sperm Grow Kit Powder and Capsule (claimed to treat sexual impotence)
  • Migrocare Capsules (claimed to treat vision problems)
  • Cysto Care Syrup (claimed to treat irregular menstruation)
  • Asthma Care Capsules (claimed to treat asthma)

The raid took place at Sri Siddhi Vinayaka Medical Hall in Nalgonda. DCA officials said that the seized medicines were worth Rs 2,750.

“Persons who make misleading advertisements regarding drugs for treatment of certain diseases and disorders are punishable under Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, with imprisonment which may extend to six months, or with fine, or with both,” the DCA said.

The authorities said that further investigation was underway and action would be taken against all offenders as per the law.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices